SGO 2019: Dendritic Cell Vaccine Plus Chemotherapy in Ovarian Cancer
Posted: Thursday, March 28, 2019
According to a study presented at the 2019 Society of Gynecologic Oncology’s (SGO) Annual Meeting on Women’s Cancer in Honolulu (Abstract 35), a new dendritic cell–based immunotherapy may improve survival among women with recurrent, epithelial ovarian cancer when added to standard chemotherapy. Although the authors observed no significant difference in progression-free survival, survival curves trended in favor of those treated with the new immunotherapy. The high tolerance and safety profile may make this treatment approach a future option for these women.
“There are currently not many alternatives in clinical development with such promising results,” David Cibula, MD, PhD, of the University and General Faculty Hospital, Prague, said in an SGO press release.
The phase III trial randomly assigned 64 patients with recurrent ovarian cancer equally to 2 groups. Group A received standard chemotherapy plus the dendritic cell vaccine, and group B received standard chemotherapy alone.
There was no significant difference in progression-free survival between the two groups (11.3 months for group A vs. 10.1 months for group B; P = .003). However, patients in group A achieved a higher 2-year survival rate of 72.4% than did those in group B (40.9%). The median overall survival was also higher among those treated with the dendritic cell vaccine: group A reached 35.5 months, whereas group B reached 22.1 months. Most adverse events were related to chemotherapy and included thrombocytopenia, anemia, neutropenia, and leukopenia.
Disclosure: The study authors’ disclosure information may be found at sgo.confex.com.